Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Clinical consequences of polymorphic drug oxidation.

Fundamental & clinical pharmacology - 1 Jan 1991

Alván G

Abstract excerpt

Many characters are genetically regulated as polymorphisms. This means that discrete groups are seen within the distribution of a certain character. Drug metabolism is no exception and the polymorphism of acetylation is recognised since the 50's. Polymorphic drug oxidation was discovered in the 70's and has been extensively studied. There are two fully established polymorphisms in drug oxidation named as the...

Topics

Debrisoquin
Humans
Oxidation-Reduction
Pharmaceutical Preparations
Phenotype
Polymorphism, Genetic

Source

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Identifiers

PMID: 1937350
DOI: 10.1111/j.1472-8206.1991.tb00713.x

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 29 Aug 2026. Prepared record publication-1937350-2026-08-29.1. Manifest publication-graph-cohort-2026-08-29.1.

Source receipt: PubMed via Helena Literature Corpus, retrieved 29 Aug 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Clinical consequences of polymorphic drug oxidation.PMID 1937350Read ↗

Genetically determined adverse drug reactions involving metabolism.Semantic proximity Read ↗

[Knowledge about metabolic capacity is important in drug therapy].Semantic proximity Read ↗

The polymorphic oxidation of beta-adrenoceptor antagonists. Clinical pharmacokinetic considerations.Semantic proximity Read ↗

Cytochrome P450: genetic polymorphism and drug interactions.Semantic proximity Read ↗

Pharmacogenetics of Debrisoquine and its Use as a Marker For CYP2D6 Hydroxylation CapacitySemantic proximity Read ↗

Molecular mechanisms of genetic polymorphisms of drug metabolism.Semantic proximity Read ↗

Prediction of phenotype for acetylation and for debrisoquine hydroxylation by DNA-tests in healthy human volunteers.Semantic proximity Read ↗

Influence of debrisoquine hydroxylation phenotype on the pharmacokinetics of mexiletine.Semantic proximity Read ↗

Genetic polymorphisms of drug metabolism.Semantic proximity Read ↗

pNAT and CYP2D6 gene polymorphism in epileptic patients.Semantic proximity Read ↗

[Pharmacogenetics of antidepressant metabolism. Value of the debrisoquin test].Semantic proximity Read ↗

Propafenone in a usual dose produces severe side-effects: the impact of genetically determined metabolic status on drug therapy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.